3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Oropharyngeal Neoplasms
2
Adenocarcinoma
2
Stomatitis
1
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
1
Recurrence
1
Prostate Adenocarcinoma
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Malignant Liver Neoplasm
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Eyelid Squamous Cell Carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Radiotherapy, Image-Guided
×
90 days
×
Clear all
NCT05328505
2026-03-24
MIDAS-Prostate
University Health Network, Toronto
Phase NA
Recruiting
80 enrolled